Infinium Pharmachem Ltd Board Meeting

222.95
(-1.09%)
Jul 23, 2024|03:32:44 PM

Infinium Pharma CORPORATE ACTIONS

24/07/2023calendar-icon
23/07/2024calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting7 Jun 202431 May 2024
1. To consider and approve issue of 19,56,000 fully convertible warrants on preferential basis subject to approval of members.2. To consider and approve investments, giving loans & guarantees and security in excess of limits specified under section 186 of the Companies Act, 2013.3. To consider and approve for giving loan or guarantee or providing security in connection with loan availed by any of the companys subsidiary(ies) or any other person specified under section 185 of the companies Act, 2013.4. To consider and approve investment in M/s Infinium Healthcare Pvt. Ltd, making it a subsidiary of the Company. Infinium Pharmachem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 INFINIUM PHARMACHEM LIMITED has informed the Exchange about Board Meeting to be held on 07-Jun-2024 to consider Fund raising. (As Per NSE Announcement Dated on 05/06/2024) 1. Considered and approved issue of up to 19,56,000 (Nineteen Lacs Fifty Six Thousand only) fully convertible warrants to be convertible at the option of the warrant holders in one or more tranches, within 18 (eighteen) months from the date of its allotment into equivalent number of fully paid up equity shares of the Company of face value of Rs. 10/- (Rupees Ten only) each for cash at an issue price of Rs.227.54/- (Rupees Two Hundred Twenty Seven and Fifty Four Paisa only) per warrant determined in accordance with the provisions of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ( ICDR Regulations ) aggregating upto Rs. 44,50,68,240/- (Rupees Forty Four Crores Fifty Lakhs Sixty Eight Thousand Two Hundred Forty Only) and to issue fresh equity shares on conversion of warrants on such terms and conditions as may be approved by the members to the persons ( Proposed Allottees ) in the manner set out in Annexure I.2. Considered and approved investments, giving loans & guarantees and security upto Rs. 100/- Crore (Rupees One Hundred Crores) over and above the limit of 60% of the paid- up share capital, free reserves and securities premium account of the Company or 100% of free reserves and securities premium account, subject to approval of members in general meeting.3. Considered and approved for giving loan or guarantee or providing security in connection with loan availed by any of the companys subsidiary(ies) or any other person specified under section 185 of the companies Act, 2013 of an aggregate amount not exceeding Rs. 100/- crores (Rupees One Hundred Crores Only) subject to approval of members in general meeting.4. Considered and approved investment of 1,25,00,000 Equity Shares at Rs. 16/- per share (57.6% investment) of M/s Infinium Healthcare Pvt. Ltd, making it a subsidiary of the Company, subject to approval of members in general meeting.5. Considered and approved valuation report issued by Manish Santosh Buchasia, Registered Valuer (IBBI Registration No. IBBI/RV/03/2019/12235). (As Per NSE Announcement Dated on 07/06/2024)
Board Meeting29 May 202422 May 2024
To consider and approve the audited financial results for the period ended March 31, 2024 and other business matters Infinium Pharmachem Limited has informed the Exchange regarding Board meeting held on May 29, 2024. (As Per NSE Announcement Dated on: 29/05/2024)
Board Meeting20 Feb 202412 Feb 2024
To review business operations of the Company. Infinium Pharmachem Limited has informed the Exchange regarding Board meeting held on February 20, 2024. (As Per NSE Announcement Dated on: 20/02/2024)
Board Meeting27 Oct 202318 Oct 2023
To consider and approve the financial results for the period ended September 30, 2023 and other business matters Infinium Pharmachem Limited has informed the Exchange regarding Board meeting held on October 27, 2023. (As Per NSE Announcement Dated on: 27/10/2023)
Board Meeting14 Sep 20234 Sep 2023
To consider allotment of bonus shares and other business matters Infinium Pharmachem Limited has informed the Exchange regarding Board meeting held to consider allotment of bonus equity shares on September 14, 2023. (As Per NSE announcement Dated on: 14/09/2023)
Board Meeting2 Aug 202319 Jul 2023
To consider bonus and other business matters Infinium Pharmachem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 (As Per NSE Announcement Dated on 20/07/2023) Infinium Pharmachem Limited has informed the Exchange that the Board of Directors at its meeting held on August 02, 2023, have considered and approved bonus at the ratio of 1 : 1, i.e 1 Equity Shares for every 1 Equity Shares held. Infinium Pharmachem Limited has informed the Exchange regarding Board meeting held on August 02, 2023. (As Per NSE Announcement Dated on 02/08/2023)

Infinium Pharma: Related News

No record found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.